The panelists share their thoughts on the future of diagnostic tests and what changes they are looking forward to, such as developing better systems to integrate clinical information with molecular data and increased FDA oversight.
The panelists share their thoughts on the future of diagnostic tests and what changes they are looking forward to.
Bryan Loy, MD, MBA, is optimistic about the future, but recognizes that the issues of accountability and FDA governance are the least of the concerns in the area of diagnostic testing.
Daniel F. Hayes, MD, believes having more consistent regulations by making things harder will actually make things easier to get new markers out.
Francisco J. Esteva, MD, PhD, said better systems need to be developed to integrate the clinical information with molecular data to ensure patients get the appropriate care.
John L. Fox, MD, MHA, is also looking forward to increased FDA oversight, although he added that it will still remain to be seen whether the medical community can ensure the tests are used appropriately so the right patients receive the right treatment.